Literature DB >> 30194955

Adipokine and cytokine levels in patients with adrenocortical cancer, subclinical Cushing's syndrome and healthy controls.

Anna Babinska1, Mariusz Kaszubowski2, Piotr Kmieć3, Krzysztof Sworczak4.   

Abstract

INTRODUCTION: In recent years researchers have focused at hormonal activity in Cushing's syndrome (CS) in connection with metabolic disorders and the role of adipokines and cytokines secreted by the adipose tissue. The aim of the study was to investigate levels of adipokines and cytokines in patients with: subclinical CS (SCS) - in relation to hormonal parameters of hypercortisolemia, and, adrenocortical cancer (ACC).
MATERIALS AND METHODS: The study included 20 SCS as well as 7 ACC patients, and 18 healthy participants. Hormonal activity and serum concentrations of adiponectin, leptin, resistin, tumor necrosis factor alpha (TNFα), interleukin 6 (IL6), and monocyte chemoattractant protein 1 (MCP1), were analyzed.
RESULTS: In SCS patients compared to healthy volunteers a trend toward higher concentrations of all pro-inflammatory cytokines was noted, however, statistically significant differences were only found for TNFα and IL6 (p = 0.047 and p = 0.028, respectively). Adiponectin concentrations were significantly lower in the SCS group (p = 0.006). Serum adipokine and cytokine levels were independent of the presence of diabetes mellitus (DM) and hypertension (HT) in the SCS group. A significant correlation was found between subclinical glucocorticoid secretion and IL6 concentration (Pearson's r = 0.517, p = 0.02). Acquired results were independent of BMI. In ACC patients compared to controls higher IL6, TNFα and MCP1 levels were recorded.
CONCLUSION: It is possible that higher adipokine and pro-inflammatory cytokine concentrations as well as lower anti-inflammatory adiponectin concentrations comprise an additional risk factor of metabolic and cardiovascular diseases in SCS patients. It seems that at least among patients with SCS adipokine and cytokine secretion is independent of hormonal activity (except for IL6).
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adipokines; Adrenocortical carcinoma (ACC); Cytokines; Subclinical Cushing syndrome (SCS)

Mesh:

Substances:

Year:  2018        PMID: 30194955     DOI: 10.1016/j.steroids.2018.08.011

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  4 in total

1.  Cardiovascular and metabolic risk factors in patients with subclinical Cushing.

Authors:  Luigi Petramala; Federica Olmati; Antonio Concistrè; Riccardo Russo; Martina Mezzadri; Maurizio Soldini; Giuseppe De Vincentis; Gino Iannucci; Giorgio De Toma; Claudio Letizia
Journal:  Endocrine       Date:  2020-04-16       Impact factor: 3.633

2.  Construction of a risk signature for adrenocortical carcinoma using immune-related genes.

Authors:  Yang Fu; Shanshan Sun; Jianbin Bi; Chuize Kong
Journal:  Transl Androl Urol       Date:  2020-10

Review 3.  The Role of Biomarkers in Adrenocortical Carcinoma: A Review of Current Evidence and Future Perspectives.

Authors:  Maja Mizdrak; Tina Tičinović Kurir; Joško Božić
Journal:  Biomedicines       Date:  2021-02-10

4.  Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors.

Authors:  Nadia Sawicka-Gutaj; Hanna Komarowska; Dawid Gruszczyński; Aleksandra Derwich; Anna Klimont; Marek Ruchała
Journal:  J Clin Med       Date:  2022-09-22       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.